Your browser doesn't support javascript.
loading
In Silico Approaches In Carcinogenicity Hazard Assessment: Current Status and Future Needs.
Tice, Raymond R; Bassan, Arianna; Amberg, Alexander; Anger, Lennart T; Beal, Marc A; Bellion, Phillip; Benigni, Romualdo; Birmingham, Jeffrey; Brigo, Alessandro; Bringezu, Frank; Ceriani, Lidia; Crooks, Ian; Cross, Kevin; Elespuru, Rosalie; Faulkner, David M; Fortin, Marie C; Fowler, Paul; Frericks, Markus; Gerets, Helga H J; Jahnke, Gloria D; Jones, David R; Kruhlak, Naomi L; Lo Piparo, Elena; Lopez-Belmonte, Juan; Luniwal, Amarjit; Luu, Alice; Madia, Federica; Manganelli, Serena; Manickam, Balasubramanian; Mestres, Jordi; Mihalchik-Burhans, Amy L; Neilson, Louise; Pandiri, Arun; Pavan, Manuela; Rider, Cynthia V; Rooney, John P; Trejo-Martin, Alejandra; Watanabe-Sailor, Karen H; White, Angela T; Woolley, David; Myatt, Glenn J.
Affiliation
  • Tice RR; RTice Consulting, Hillsborough, North Carolina, 27278, USA.
  • Bassan A; Innovatune srl, 35129 Padova, Italy.
  • Amberg A; Sanofi Preclinical Safety, Industriepark Höchst, 65926 Frankfurt, Germany.
  • Anger LT; Genentech, Inc., South San Francisco, California, 94080, USA.
  • Beal MA; Healthy Environments and Consumer Safety Branch, Health Canada, Government of Canada, Ottawa, Ontario, Canada K1A 0K9.
  • Bellion P; DSM Nutritional Products Ltd., Kaiseraugst, Switzerland.
  • Benigni R; Alpha-Pretox, Rome, Italy.
  • Birmingham J; GlaxoSmithKline, David Jack Centre for R&D, Ware, Hertfordshire, SG12 0DP, United Kingdom.
  • Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation, Center Basel, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland.
  • Bringezu F; Merck Healthcare KGaA, 64293 Darmstadt, Germany.
  • Ceriani L; Humane Society International, 1000 Brussels, Belgium.
  • Crooks I; British American Tobacco (Investments) Ltd, GR&D Centre, Southampton, SO15 8TL, United Kingdom.
  • Cross K; Instem, Columbus, Ohio, 43215, USA.
  • Elespuru R; Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, Maryland, 20993, USA.
  • Faulkner DM; Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
  • Fortin MC; Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey, 08855, USA.
  • Fowler P; FSTox Consulting (Genetic Toxicology), Northamptonshire, United Kingdom.
  • Frericks M; BASF SE, Limburgerhof, Germany.
  • Gerets HHJ; UCB BioPharma SRL, Braine-L'Alleud, Belgium.
  • Jahnke GD; Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, 27709, USA.
  • Jones DR; Clinical Trials Unit, MHRA, London E14 4PU.
  • Kruhlak NL; Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland, 20993, USA.
  • Lo Piparo E; Chemical Food Safety Group, Nestlé Research, CH-1000 Lausanne 26, Switzerland.
  • Lopez-Belmonte J; Cuts Ice Ltd Chemical Food Safety Group, Nestlé Research, CH-1000 Lausanne 26, Switzerland.
  • Luniwal A; North American Science Associates (NAMSA) Inc., Minneapolis, Minnesota, 55426, USA.
  • Luu A; Healthy Environments and Consumer Safety Branch, Health Canada, Government of Canada, Ottawa, Ontario, Canada K1A 0K9.
  • Madia F; European Commission, Joint Research Centre (JRC), Ispra, Italy.
  • Manganelli S; Chemical Food Safety Group, Nestlé Research, CH-1000 Lausanne 26, Switzerland.
  • Manickam B; Pfizer Inc, Groton, Connecticut, 06340, USA.
  • Mestres J; IMIM Institut Hospital Del Mar d'Investigacions Mèdiques and Universitat Pompeu Fabra, Doctor Aiguader 88, Parc de Recerca Biomèdica, 08003 Barcelona, Spain; and Chemotargets SL, Baldiri Reixac 4, Parc Científic de Barcelona, 08028, Barcelona, Spain.
  • Mihalchik-Burhans AL; Gad Consulting Service, Raleigh, NC, 27609, USA.
  • Neilson L; Broughton Nicotine Services, Oak Tree House, Earby, Lancashire, BB18 6JZ United Kingdom.
  • Pandiri A; Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, 27709, USA.
  • Pavan M; Innovatune srl, 35129 Padova, Italy.
  • Rider CV; Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, 27709, USA.
  • Rooney JP; Integrated Laboratory Systems, LLC., Morrisville, North Carolina, 27560, USA.
  • Trejo-Martin A; Gilead Sciences Inc in Foster City, CA.
  • Watanabe-Sailor KH; School of Mathematical and Natural Sciences, Arizona State University, West Campus, Glendale, Arizona, 85306, USA.
  • White AT; GlaxoSmithKline, David Jack Centre for R&D, Ware, Hertfordshire, SG12 0DP, United Kingdom.
  • Woolley D; ForthTox Limited, Linlithgow, United Kingdom.
  • Myatt GJ; Instem, Columbus, Ohio, 43215, USA.
Comput Toxicol ; 202021 Nov.
Article de En | MEDLINE | ID: mdl-35368437
ABSTRACT
Historically, identifying carcinogens has relied primarily on tumor studies in rodents, which require enormous resources in both money and time. In silico models have been developed for predicting rodent carcinogens but have not yet found general regulatory acceptance, in part due to the lack of a generally accepted protocol for performing such an assessment as well as limitations in predictive performance and scope. There remains a need for additional, improved in silico carcinogenicity models, especially ones that are more human-relevant, for use in research and regulatory decision-making. As part of an international effort to develop in silico toxicological protocols, a consortium of toxicologists, computational scientists, and regulatory scientists across several industries and governmental agencies evaluated the extent to which in silico models exist for each of the recently defined 10 key characteristics (KCs) of carcinogens. This position paper summarizes the current status of in silico tools for the assessment of each KC and identifies the data gaps that need to be addressed before a comprehensive in silico carcinogenicity protocol can be developed for regulatory use.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Comput Toxicol Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Comput Toxicol Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...